Tenax Therapeutics, Inc. (TENX) · Nov 5, 2026 · Earnings
Beat — EPS $(0.31) vs roughly $(0.35)–$(0.37) consensus
Tenax Therapeutics beat Q3 earnings expectations and extended its runway, but the central LEVEL-2 strategy remains unvalidated pending FDA feedback.
Tenax is a cash-funded, Phase 3 biotech trying to salvage its oral levosimendan program after the broad LEVEL trial missed its primary endpoint; the company is now narrowing LEVEL-2 toward the sicker patients who appeared to respond better. That rescue strategy was already disclosed on October 8, 2026, so this filing mostly confirms the plan rather than creating a new clinical inflection.
The quarter beat the limited financial benchmark. Reported EPS of $(0.31) was better than the published consensus range of roughly $(0.35) to $(0.37), making this a narrow earnings beat rather than a major operating surprise. The improvement is not coming from revenue—Tenax remains a development-stage company—but from quarterly spending and interest income.
| Q3 2026 | Q3 2025 | Consensus | |
|---|---|---|---|
| EPS (Income Statement) | $(0.31) | $(0.40) | $(0.35)–$(0.37) |
| Net loss (Income Statement) | $(16.7)M | $(15.8)M | |
| R&D expense (Income Statement) | $12.1M | $10.3M | |
| Cash and equivalents (Balance Sheet) | $113.7M |
The important business change is regulatory engagement, not the earnings line. Tenax says it has now received a Type C meeting with the FDA to discuss levosimendan’s overall development, a meaningful next step because the amended LEVEL-2 design is based on post hoc subgroup analysis rather than a successful overall LEVEL result. The filing states that “Tenax shared the topline LEVEL results with the FDA in mid-August and has been granted a Type C meeting to discuss the overall development of levosimendan in PH-HFpEF.” 〔0〕
The clinical thesis remains plausible but unproven. The company is targeting patients with lower exercise capacity and signs of greater cardiac volume overload after observing a 34-meter treatment advantage in that subgroup, but the original Phase 3 trial still failed its primary endpoint across the enrolled population. The filing explicitly says “LEVEL did not meet its primary endpoint of improvement in 6MWD versus placebo.” The amended trial may improve the odds of finding a responsive population, but it also introduces enrollment and regulatory risk because the enrichment approach came from post hoc analysis.
Funding is no longer the immediate constraint, though the runway is conditional. Tenax ended September with $113.7 million in cash and says its current plan funds operations through fiscal 2028, giving it room to continue LEVEL-2 without an immediate financing event. However, the company also says that operating plan is subject to change after the FDA meeting. 〔1〕
Bottom line: This is a narrow financial beat and a modestly better funding-and-regulatory setup, but it does not repair the core clinical setback. The business story remains a high-risk attempt to validate a narrower LEVEL-2 population with FDA support still pending.
Type C FDA meeting; LEVEL-2 protocol update in Q1 2027
A buy-side analyst on every ticker — it reads every public company's filing the instant it drops and decodes it into plain English.
A buy-side analyst on every ticker — the whole market decoded the second it moves, before it's a headline. Free gives you a taste. Pro takes the cap off and opens the full read on every company.
by Signing in NOW, claim your FREE 14-day Pro trial!